Corline Biomedical AB (OSTO:CLBIO) GF Value Rank: 1 (As of Sep. 15, 2026) — 50% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:CLBIO Corline Biomedical AB OSTO:CLBIO
41 GF Score
Price kr15.70
GF Value kr8.88
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Corline Biomedical AB GF Value Rank?

Corline Biomedical AB OSTO:CLBIO +4.67% 41 GF Value Rank is 1 as of Sep. 15, 2026, which is 50% below its 10-year median of 2.00. GuruFocus rates OSTO:CLBIO with a GF Score™ of 41/100 and a GF Value™ of kr8.88 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Corline Biomedical AB has the GF Value Rank of 1.

GF Value Rank evaluates the exclusive GuruFocus valuation and performance of a stock, rated on a scale from 1 to 10. It is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.

GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).

We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.

After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.

A higher score indicates a stock with a relatively low valuation and substantial potential for outperformance. Conversely, a lower score often reflects stocks that are either highly overvalued or deeply undervalued, both of which tend to underperform.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Corline Biomedical AB GF Value Rank Related Terms

OSTO:CLBIO vs VRTX, REGN, MRNA: GF Value Rank Comparison

For the Biotechnology subindustry, Corline Biomedical AB's GF Value Rank, along with its competitors' market caps and GF Value Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Corline Biomedical AB GF Value Rank vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Corline Biomedical AB's GF Value Rank distribution charts can be found below:

* The bar in red indicates where Corline Biomedical AB's GF Value Rank falls into.


OSTO:CLBIO
41GF Score
Corline Biomedical AB OSTO:CLBIO
GF Value Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Value Rank →
What does a GF Value Rank of 1 mean?
Corline Biomedical AB (OSTO:CLBIO) has a GF Value Rank of 1 as of Sep. 15, 2026. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on Corline Biomedical AB and its competitors. This is 50% below median its historical median of 2.00. Over the past decade, Corline Biomedical AB's GF Value Rank has ranged from 1.00 to 10.00.
Is Corline Biomedical AB's GF Value Rank too high?
Corline Biomedical AB's current GF Value Rank of 1 is 50% below median its 10-year median of 2.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 10.00. Overall, Corline Biomedical AB has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Corline Biomedical AB's GF Value Rank compare to VRTX and REGN?
Corline Biomedical AB's GF Value Rank of 1 can be compared against companies in the Biotechnology industry. Historically, Corline Biomedical AB's own GF Value Rank has ranged from 1.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Value Rank for a Biotechnology company?
A good GF Value Rank depends on the Biotechnology industry context. However, GF Value Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Value Rank mean?
A high GF Value Rank can signal that a stock is expensive relative to its fundamentals. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on Corline Biomedical AB and its competitors. Corline Biomedical AB's current GF Value Rank is 1, which is 50% below median its own 10-year median of 2.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corline Biomedical AB stock overvalued right now?
Based on GuruFocus' analysis, Corline Biomedical AB (OSTO:CLBIO) is currently considered Significantly Overvalued. The stock's GF Value™ is kr8.88, compared to a current price of kr15.70 — trading 76.8% above its estimated fair value. The current GF Value Rank is 1, which is 50% below median its 10-year median of 2.00. Corline Biomedical AB's overall GF Score™ is 41/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Value Rank calculated?
GF Value Rank is calculated from a company's financial statements. For Corline Biomedical AB (OSTO:CLBIO), the current GF Value Rank is 1 as of Sep. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Corline Biomedical AB (OSTO:CLBIO) Overvalued in 2026?

Based on GuruFocus' analysis, Corline Biomedical AB stock appears to be overvalued. The current stock price of kr15.70 is trading 76.8% above its estimated GF Value™ of kr8.88. GuruFocus considers Corline Biomedical AB to be Significantly Overvalued.

Key valuation signals for OSTO:CLBIO:

  • GF Value Rank: 1 (50% below median its 10-year median of 2.00)
  • GF Value™: kr8.88 vs. price of kr15.70 (76.8% above fair value)
  • GF Score™: 41/100 with 4 warning signs

No single metric tells the full story. See the OSTO:CLBIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Corline Biomedical AB Business Description

Address Lefflersgatan 5, Uppsala, SWE, 754 50
Corline Biomedical AB offers customers in the medical technology industry and regenerative medicine as well as transplant clinics products to manage immune thrombosis. The company offers a proprietary surface treatment technology, Corline Heparin Surface (CHS), which can be used in combination with all commonly used implant materials such as polymers (plastics) and various metals, but also for equipment where blood circulation occurs outside the body.
41GF Score

Get the complete analysis for OSTO:CLBIO

GF Value Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr15.70
Price
kr8.88
GF Value